Wegovy vs. Zepbound: Head-to-Head for Weight Loss in 2026

Prices verified May 22, 2026 · Updated for 2026

The two heavyweights of prescription weight loss

Wegovy (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly) are the two FDA-approved medications that define the current weight loss landscape. If you're researching prescription weight loss options, you're almost certainly choosing between these two. This comparison uses the most current 2026 data available, including the head-to-head SURMOUNT-5 trial and the latest pricing changes from both manufacturers.

Mechanism: single vs. dual agonist

Wegovy activates the GLP-1 receptor—one hormonal pathway that regulates appetite, stomach emptying, and insulin sensitivity. Zepbound activates both GLP-1 and GIP receptors, adding a second hormonal pathway that enhances insulin response and may boost fat metabolism. The dual-agonist approach is the primary driver of Zepbound's superior weight loss numbers.

Weight loss results

Novo Nordisk is developing Wegovy HD (a higher 7.2mg dose) that showed approximately 19% weight loss in Phase 3—narrowing the gap with Zepbound. FDA filing is expected in 2026, with potential approval in 2027. Until then, at currently approved doses, Zepbound maintains a roughly 6-percentage-point advantage.

FDA-approved indications

Wegovy's cardiovascular indication is significant: the SELECT trial showed a 20% reduction in major adverse cardiovascular events. No other weight loss medication has this evidence. Zepbound's cardiovascular outcomes trial is ongoing.

Pricing comparison (May 2026)

*Foundayo is orforglipron, a different molecule than tirzepatide, but manufactured by Eli Lilly and positioned as an oral alternative in the Lilly weight loss portfolio.

Novo Nordisk announced it will cut Wegovy's list price to $675/mo starting January 2027—a roughly 50% reduction that could reshape the competitive landscape.

Side effects

Both share the standard GLP-1 side effect profile: nausea, diarrhea, constipation, and vomiting, primarily during dose escalation. GI side effects affect roughly 40–50% of patients on either medication, with most resolving within the first 4–8 weeks.

Zepbound's more gradual titration schedule (six dose levels vs. five for Wegovy) may produce a smoother side effect curve. Both carry the same boxed warning regarding thyroid C-cell tumors and are contraindicated with personal or family history of medullary thyroid carcinoma.

Format and convenience

Wegovy has a significant format advantage: it's available as a weekly injection and a daily pill. The Wegovy pill eliminates the needle barrier entirely, though it requires strict fasting conditions. Zepbound is injection-only (the new KwikPen offers a simpler injection device), though Eli Lilly's oral option Foundayo (orforglipron) provides a pill alternative within the Lilly ecosystem—albeit with lower weight loss results and a different active ingredient.

Our verdict

For patients whose primary goal is maximum weight loss and who are comfortable with injections, Zepbound is the stronger performer at currently approved doses. The dual-agonist mechanism consistently produces about 6 percentage points more weight loss.

For patients who want proven cardiovascular protection, the option of an oral formulation, or the most established safety data, Wegovy is the more complete package. It's been on the market longer, has more FDA indications, and offers more ways to take it.

For cash-pay patients seeking the lowest cost, compounded semaglutide (the Wegovy equivalent) is more affordable than compounded tirzepatide (the Zepbound equivalent). Both are available through verified telehealth providers.